ALKERMES | ALKS - 销售和管理费用

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 7.78B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	销售和管理费用	更改		日
AbbVie	USD 3.58B		316M	2026-03
Acadia Pharmaceuticals	USD 160.79M		14.06M	2026-03
ALKERMES	USD 264.59M		77.4M	2026-03
Amgen	USD 1.58B		354M	2026-03
Biogen	USD 554.3M		128.2M	2026-03
BioMarin Pharmaceutical	USD 258.28M		63.92M	2026-03
Bristol-Myers Squibb	USD 1.62B		564M	2026-03
Coherus Biosciences	USD 15M		6.26M	2025-12
Eli Lilly	USD 2.93B		198M	2026-03
Gilead Sciences	USD 1.45B		326M	2026-03
Heron Therapeutics	USD 23.74M		605K	2025-12
Ionis Pharmaceuticals	USD 151M		21M	2026-03
J&J	USD 6.03B		719M	2026-03
Malin Corporation	EUR 1.1M		400K	2024-12
Merck	USD 2.67B		180M	2026-03
Minerva Neurosciences	USD 2.48M		58.79K	2024-09
Nektar Therapeutics	USD 10.17M		10.17M	2025-12
Neurocrine Biosciences	USD 318.5M		16.7M	2026-03
Otsuka Holdings	JPY 259.49B		18.81B	2026-03
Ovoca Bio	EUR 632K		2.33M	2025-06
Pfizer	USD 2.92B		1.16B	2026-03
Regeneron Pharmaceuticals	USD 647.7M		127.3M	2026-03
Vertex Pharmaceuticals	USD 493.7M		6.7M	2026-03